Demystifying Medicine Video

This video presents the therapeutics currently available for the treatment and management of amyotrophic lateral sclerosis (ALS). It describes the pathophysiology of ALS as well as the progression of the disease. It examines the symptoms of ALS. It then discusses the two-pronged treatment approach that includes the prescription of pharmaceuticals that slow the progression of ALS, and the management of symptoms through various symptom-directed therapies. Finally, the video looks at stem-cell based therapies that are in development for the treatment of ALS.

[To learn more about ALS, visit the Canada ALS Society]

[Please complete our feedback form]

  • Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. The Lancet. 2011;377(9769):942-55.
  • ALS Association. (2018) What is ALS? Retrieved Nov. 7, 2018.
  • Galvin M, Gaffney R, Corr B, Mays I, Hardiman O. From first symptoms to diagnosis of amyotrophic lateral sclerosis: perspectives of an Irish informal caregiver cohort—a thematic analysis. BMJ open. 2017 Mar 1;7(3):e014985.
  • Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. The Lancet Neurology. 2018;17(5):385-6.
  • Yeo CJ, Simmons Z. Discussing edaravone with the ALS patient: an ethical framework from a US perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19(3-4):167-72.
  • Phukan J, Hardiman O. The management of amyotrophic lateral sclerosis. Journal of Neurology.2009;256(2):176.
  • Mayo Clinic. (2018) Amyotrophic lateral sclerosis (ALS) — Diagnosis and treatment. Retrieved Nov. 4, 2018.
  • Lunn JS, Sakowski SA, Feldman EL. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells. 2014;32(5):1099-109.
  • Forostyak S, Sykova E. Neuroprotective potential of cell-based therapies in ALS: from bench to bedside. Frontiers in Neuroscience.2017;11:591.